

GlaxoSmithKline plc (NYSE: GSK) announced Wednesday the United States Food and Drug Administration had approved its cancer drug aimed at treating refractory...
You can purchase shares of GENMAB A/S DKK by Genmab A/S (OTCPK:GNMSF) through any online brokerage.
There are no as such competitors for GENMAB A/S DKK by Genmab A/S.
There is no analysis for GENMAB A/S DKK by Genmab A/S to provide a consensus price target.
The stock price for GENMAB A/S DKK by Genmab A/S (OTCPK: GNMSF) is $563.82 last updated October 30, 2026 at 11:59 AM EDT.
There are no upcoming dividends for GENMAB A/S DKK by Genmab A/S.
GENMAB A/S DKK by Genmab A/S does not have any upcoming earnings scheduled.
There is no upcoming split for GENMAB A/S DKK by Genmab A/S.
GENMAB A/S DKK by Genmab A/S is in the Health Care sector and Biotechnology industry. They are listed on the OTCPK.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab...